Developed by BioAlliance Pharma, Loramyc is a mucoadhesive gingival tablet containing miconazole administered once-a-day over 7 to 14 days.
Additionally, Therabel has made a fully dedicated team and has also signed a co-promotion agreement with Hikma Pharma for Loramyc business in Germany.
BioAlliance Pharma CEO Dominique Costantini said they are confident in Therabel and Hikma teams’ involvement and know-how to ensure Loramyc success in Germany.